Piper Sandler analyst Do Kim raised the firm’s price target on Vertex Pharmaceuticals to $296 from $293 and keeps a Neutral rating on the shares. Focus should continue to increase on late-stage pipelines as cystic fibrosis growth slows, the analyst tells investors. While Kim expects exa-cel to be approved, the timing of this may be a risk due to it being the first gene-editing based therapy to be approved.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals initiated with a Hold at Canaccord
- SVB Securities upgrades Vertex to Outperform, raises price target to $374
- Vertex Pharmaceuticals upgraded to Outperform at SVB Securities
- Vertex Pharmaceuticals expands collaboration with Arbor Biotechnologies
- Opco reveals three biotech stocks that will outperform in 2023